Latest Unigene Stories

BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer will be presenting a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York, NY. Mr. Palmer's presentation is scheduled to begin at 11:00 a.m. ET on Monday, February 13, 2012. Individuals can listen to a...

BOONTON, N.J., Feb. 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has received the 2012 Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category in recognition of the Company's 2011 clinical advances in the oral delivery of peptides. This year's DDP Award recipients were voted on and selected by conference attendees, including leading scientists, pharmaceutical executives and drug delivery key...

BOONTON, N.J., Jan. 9, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that have the potential to monetize assets and unlock significant value over the next 12 months. Management believes the key elements are in place to address the Company's debt and begin restructuring the balance sheet in 2012. Unigene's CEO, Senior Management and Board of Directors signaled confidence...

BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase(TM) 2012 in San Francisco, CA on Monday, January 9, 2012 at 11:30 a.m. PT (2:30 p.m. ET). Mr. Palmer's presentation will include an overview of Unigene's industry-leading oral...

BOONTON, N.J., Dec. 19, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today highlighted its significant accomplishments in 2011 and announced that its management team has put key elements in place to begin addressing the capital structure and eliminating the inherited debt. Unigene also reaffirmed that the Company's projected cash flow is expected to fund operations into the second half of 2012, following a corporate reorganization to better strategically...

BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will be presenting a corporate overview at the 22nd Annual Oppenheimer Healthcare Conference being held in New York City. Mr. Palmer's live presentation is scheduled to begin at 4:10 p.m. ET on Tuesday, December 13, 2011. A live...

BOONTON, N.J., Nov. 16, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the appointment of Thomas J. Sabatino, Jr. to its Board of Directors. Mr. Sabatino is currently Executive Vice President and General Counsel for Walgreen Co., (NYSE: WAG) (NASDAQ: WAG), based in Deerfield, IL. He joined Walgreens in September 2011 after having held general counsel roles with...

BOONTON, N.J., Nov. 10, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer will be presenting a corporate overview at the Lazard Capital Markets 8th Annual Healthcare Conference. Mr. Palmer's live presentation is scheduled to begin at 1:00 p.m. ET on Wednesday, November 16, 2011. Individuals can listen to a live...

BOONTON, N.J., Nov. 9, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced third quarter financial results for the period ended September 30, 2011. The Company continued solid execution of its turnaround strategy and highlighted significant progress achieved in the third quarter. Ashleigh Palmer, Unigene's President and CEO stated, "We have made tremendous progress in the past...

BOONTON, N.J., Nov. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that management will report third quarter 2011 financial results before market open and host a conference call and live audio webcast on Wednesday, November 9, 2011 at 11 a.m., ET to discuss the results. Interested participants and investors may access the conference call at 11 a.m., ET by dialing...